These findings support that ETV1‐overexpressing PCa cells may be more sensitive to the synergistic interaction between TTI‐101 and Erlotinib and sustain the potential of cotargeting EGFR and STAT3 pathways as a therapeutic strategy in advanced prostate carcinomas displaying ETV1 overexpression. Here, STAT3 is linked to prostate carcinoma.